Pfizer and Lilly receive FDA Fast Track designation for tanezumab
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP). Tanezumab is an investigational humanized monoclonal antibody that selectively targets, binds to and inhibits nerve growth factor (NGF).
Bayer Grants4Apps® Dealmaker Berlin 2017
- Details
- Category: Business
Bayer Grants4Apps® is calling all mature teams, startups and companies that have a solution ready to go. The new Dealmaker is all about quality facetime between you and Grants4Apps' experts for one full day. If there is a match, you will be invited to Berlin to pitch your solution, discuss collaboration options and close a deal. Find out, if there is a mutual interest to start a bigger journey.
Boehringer Ingelheim builds Digital Lab "BI X" with focus on innovative digital solutions in healthcare
- Details
- Category: Boehringer Ingelheim
With the founding of BI X as independent subsidiary Boehringer Ingelheim will focus on breakthrough innovative digital solutions in healthcare from idea to pilot. The start-up will work closely together with all three business units of the company - Human Pharma, Animal Health and Biopharmaceuticals.
Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting
- Details
- Category: Novartis
Novartis today announced that it will present 19 scientific abstracts at the 59th Annual Scientific Meeting of the American Headache Society (June 8-11, 2017, Boston, USA). This includes a new analysis from a pivotal study highlighting the efficacy of AMG 334 (erenumab) in patients with 15 or more headache days a month (chronic migraine) and a recent history of acute migraine medication overuse.
Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the phase III ALEX study showed Alecensa® (alectinib) significantly reduced the risk of disease worsening or death (progression-free survival, PFS) by more than half (53%) compared to crizotinib when given as initial (first-line) treatment for people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (hazard ratio (HR)=0.47, 95% CI: 0.34-0.65, p<0.0001).
AstraZeneca enters agreement with Grünenthal to divest rights to migraine treatment Zomig
- Details
- Category: AstraZeneca
AstraZeneca has entered an agreement with Grünenthal for the global rights to Zomig (zolmitriptan) outside Japan. Zomig is indicated for the acute treatment of migraines and cluster headaches, an area of medicine outside AstraZeneca's strategic focus.
Call for applications: 2017 Lyfebulb-Novo Nordisk Innovation Summit and Award
- Details
- Category: Novo Nordisk
For the second year in a row, Lyfebulb and Novo Nordisk will support international patient entrepreneurs who develop innovative ideas and concepts aimed to positively empower and impact the lives of people living with type 1 or type 2 diabetes - and ultimately our societies. The Lyfebulb-Novo Nordisk Innovation Summit is based on the Lyfebulb Entrepreneur Circle, which was established in 2015.
More Pharma News ...
- Pfizer receives FDA Fast Track designation for tafamidis for transthyretin cardiomyopathy
- Bristol-Myers Squibb announces new collaboration to evaluate combination therapy in colorectal cancer
- Amgen showcases a legacy of science, innovation and collaboration in Cambridge
- Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
- At ASCO 2017 clinicians present new evidence about Watson cognitive technology and cancer care
- Anyone can become more curious. Is that true?
- Array BioPharma and Bristol-Myers Squibb announce strategic collaboration